5th Digital Pharma &amp.

‘We have to set the program today for such a growth: Processes in analysis and development have to accelerate, the IT environment has to be […]

Martin Kircher.

Nickerson, Ph.D., Jay Shendure, M.D., Ph.D., Annapurna Poduri, M.D., M.P.H., Timothy W. Yu, M.D., Ph.D., and Christopher A. Walsh, M.D., Ph.D.: Somatic Mutations in Cerebral […]

Leonie Coetzee.

Finally, there have been limitations with regards to the analysis of direct impact, which are described in Section S12 in the Supplementary Appendix. In conclusion, […]

Helgo Magnussen.

Included in a prespecified sensitivity analysis were exacerbations that were reported in individuals who were receiving open-label fluticasone therapy and in those that experienced discontinued […]

Jean-Yves Douillard.

BRAF mutations are unique of RAS mutations typically, and the clinical data suggest that the BRAF V600E mutation is certainly prognostic of patient outcome with […]

1 2 3